Skip to main content
. Author manuscript; available in PMC: 2019 Jan 4.
Published in final edited form as: Cell Stem Cell. 2018 Jan 4;22(1):78–90.e4. doi: 10.1016/j.stem.2017.11.020

Figure 1. Intraductal infusion of AAV-PM corrects ALX-induced hyperglycemia in GCG-Cre; R26RTomato mice.

Figure 1

(A) Schematic for the generation of GCG-Cre; R26RTomato mice. (B) Hyperglycemia was induced in GCG-Cre; R26RTomato mice by ALX injection. One week after ALX treatment, mice received a pancreatic intraductal infusion of either AAV-PM (red line) or control AAV-GFP (green line). Fasting blood glucose levels were measured. (C) IPGTT was performed in these mice 4 weeks after viral infusion. Untreated mice (no ALX, no virus, in blue) were used as an additional control. (D) Beta cell mass at 4 weeks after virus infusion. The contribution of INS+ cells without tomato red fluorescence is shown by the hatched bar contained within the red bar, compared to the beta cell mass in mice that received AAV-GFP viral infusion (green bar), and the beta cell mass of untreated mice (UT, no ALX, no virus, blue bar). Statistics were analyzed by one-way ANOVA with a Bonferroni correction, followed by Fisher’s Exact Test. Data are presented as mean±S.D. *: p<0.05. **: p<0.01. N=10. Scale bars are 50µm.